共 55 条
[1]
Bruix J(2010)Practice Guidelines Committee AASLD. Management of hepatocellular carcinoma: an update Hepatology 53 1020-1022
[2]
Sherman M(2008)Sorafenib in liver cancer—just the beginning N Engl J Med 359 420-422
[3]
Roberts LR(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[4]
Llovet JM(2009)Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial Lancet Oncol 10 25-34
[5]
Ricci S(2011)Response to treatment series: part 1 and introduction, measuring tumor response—challenges in the era of molecular medicine AJR Am J Roentgenol 197 15-17
[6]
Mazzaferro V(2011)Changes in tumor density in patients with advanced hepatocellular carcinoma treated with sunitinib Clin Cancer Res 17 4504-4512
[7]
Cheng AL(2009)New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1) Eur J Cancer 45 228-247
[8]
Kang YK(2010)Evaluation of response in malignant tumors treated with the multitargeted tyrosine kinase inhibitor sorafenib: a multitechnique imaging assessment AJR Am J Roentgenol 194 5-14
[9]
Chen Z(2012)Comparison of tumor response by response evaluation criteria in solid tumors (RECIST) and modified RECIST in patients treated with sorafenib for hepatocellular carcinoma Cancer 118 147-156
[10]
Sullivan DC(2010)Assessing tumor response and detecting recurrence in metastatic renal cell carcinoma on targeted therapy: importance of size and attenuation on contrast-enhanced CT AJR Am J Roentgenol 194 157-165